HUTCHMED (HCM) Stock Price, News & Analysis

Company Overview

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company combines drug research and development capabilities with commercial operations in China and international markets.

HUTCHMED’s oncology portfolio includes fruquintinib, marketed in China as Elunate and in the United States as Fruzaqla for certain patients with metastatic colorectal cancer. The company also develops other targeted therapies, including savolitinib, a MET tyrosine kinase inhibitor, and surufatinib, an angiogenesis and immunomodulatory therapy. Its pipeline includes additional investigational medicines for solid tumors and other diseases.

Founded in 2000, HUTCHMED was formerly known as Hutchison China MediTech Limited and has expanded from a China-focused drug discovery business into an international biopharmaceutical company. Its medicines and development programs are supported by activities in China, the United States, Europe and other global markets, with commercialization conducted through its own operations and collaboration partners.

Key Stats

• Today's Range: $13.57 to $13.77
• 50-Day Range: $10.77 to $14.11
• 52-Week Range: $9.77 to $17.29
• Volume: 15,795 shs
• Average Volume: 49,671 shs
• Market Capitalization: $2.39 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.87
• Consensus Rating: Hold

HUTCHMED Stock Analysis - MarketRank™

HUTCHMED scored higher than 35% of companies evaluated by MarketBeat, and ranked 734th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Hold

Consensus Rating

HUTCHMED has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 2 sell ratings.

Upside/Downside

The consensus price target for HUTCHMED is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

HUTCHMED has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -4.35%

Earnings Growth

Earnings for HUTCHMED are expected to decrease by -4.35% in the coming year, from $0.23 to $0.22 per share.

Price to Book Value per Share Ratio

HUTCHMED has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.12% of the float of HUTCHMED has been sold short.

Short Interest Ratio / Days to Cover

HUTCHMED has a short interest ratio ("days to cover") of 2.31, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HUTCHMED has recently increased by 18.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HUTCHMED does not currently pay a dividend.

Dividend Growth

HUTCHMED does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.03

News Sentiment

HUTCHMED has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for HUTCHMED this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for HCM on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HUTCHMED insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.60% of the stock of HUTCHMED is held by insiders.

Percentage Held by Institutions

8.82% of the stock of HUTCHMED is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:HCM
• CIK: 1648257
• Web: www.hutch-med.com
• Phone: 852-2121-3888
• Fax: 852-2128-1778
• Employees: 1,796
• Year Founded: 2000

Price Target and Rating

• Average Price Target for HUTCHMED: $14.87
• High Price Target: $17.00
• Low Price Target: $13.60
• Potential Upside/Downside: +8.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 5.64
• Quick Ratio: 5.50

Sales & Book Value

• Annual Sales: $548.51 million
• Price / Sales: 4.35
• Cash Flow: $2.74 per share
• Price / Cash Flow: 4.99
• Book Value: $7.17 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 174,470,000
• Free Float: 168,186,000
• Market Cap: $2.39 billion
• Optionable: Not Optionable
• Beta: 0.24